Working its way through a CRL on lead drug, Supernus taps $150M loan
As Rockville, MA-based Supernus works its way back to the FDA’s good graces with a lead Parkinson’s drug, it is tapping into a $150 million line of credit.
UBS Bank USA is providing the loan, which Supernus says can be drawn at any time at a fixed interest rate.
Supernus, which markets a number of drugs treating central nervous system diseases, reported cash, cash equivalents, current and long-term marketable securities of around $523.7 million as of the end of September. During that update, execs also predicted 2022 revenue will be $650 million to $680 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
